Press Release: Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Dow Jones08-14

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025

Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO$(R)$ and UNLOXCYT$(TM)$

MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2026.

Lindsay A. Rosenwald, M.D., Fortress' Chairman, President and Chief Executive Officer, said, "The second quarter of 2026 reflected continued momentum across our portfolio and further progress in unlocking long-term shareholder value. Our subsidiary Urica Therapeutics, Inc.'s ("Urica") equity position in Crystalys Therapeutics, Inc. ("Crystalys") was strengthened by Crystalys' $130 million Series B financing, which will support the late-stage global development and commercialization preparation for dotinurad, a next-generation oral URAT1 inhibitor for gout, on which Urica is entitled to a 3% royalty on future net sales. Journey Medical also continues to scale Emrosi(R) , securing a third major GPO contract that expanded payer access to over 150 million commercial lives. Coming off the momentum of ZYCUBO(R) 's approval and the $205 million PRV sale in the first quarter, we enter the second half of 2026 with a favorable cash balance that positions us to continue executing on our pipeline and business development priorities."

Dr. Rosenwald added, "We continued to see encouraging clinical progress this quarter on our partnered programs. AstraZeneca reported additional prespecified subgroup analyses for anselamimab (formerly CAEL-101) showing a 62% improvement in survival and a 71% reduction in cardiovascular hospitalizations among kappa predominant light chain isotype patients in the CARES program, and indicated that it plans to submit these findings to regulatory authorities. Crystalys also continues to advance dotinurad's two global Phase 3 trials while initiating a new Phase 2 study in difficult-to-treat gout, broadening the program's potential patient population. With a diversified portfolio spanning commercial, late-stage, and development-stage programs, including royalties, milestones and equity, and a strengthened balance sheet following the ZYCUBO(R) PRV monetization, we believe Fortress is well positioned to advance strategic initiatives and drive long-term value for our shareholders."

Recent Corporate Highlights(1) :

Commercial Portfolio Updates

   -- Journey Medical Expands Payer Access for Emrosi(R). At the end of March 
      2025, our partner company Journey Medical Corporation ("Journey Medical") 
      commercially launched Emrosi(R) (40mg Minocycline Hydrochloride 
      Modified-Release Capsules, consisting of 10mg immediate release and 30mg 
      extended release pellets), also known as DFD-29, for inflammatory lesions 
      of rosacea. Emrosi(R) was approved by the FDA in November 2024 and is 
      available by prescription at specialty pharmacy chains. In April 2026, 
      Journey Medical announced that it secured a contract with a third major 
      group purchasing organization (GPO) for Emrosi(R). As such, payer access 
      for Emrosi(R) expanded to over 150 million commercial lives as of April 
      1, 2026, which equates to approximately 85% of all commercial lives in 
      the United States that have access to Emrosi(R). Journey Medical reported 
      net product revenues of $17.8 million for the second quarter of 2026, 
      compared to net product revenues of $15.0 million for the second quarter 
      ended June 30, 2025. 
 
   -- Royalties. In the second quarter of 2026, Cyprium Therapeutics, Inc. 
      ("Cyprium") recognized $0.2 million in royalty revenue on net sales of 
      ZYCUBO(R), and Fortress recognized $0.1 million in royalty income 
      (contingent consideration) on net sales of UNLOXCYT(TM), following their 
      recent commercial launches. 

Clinical Updates

   -- Phase 3 CARES Results for Anselamimab (CAEL-101); Regulatory Submission 
      of Prespecified Subgroup Analysis Planned. In the second quarter of 2026, 
      AstraZeneca announced additional prespecified subgroup analyses in 
      patients with kappa predominant light chain isotype, showing that 
      anselamimab (formerly known as CAEL-101) improved survival by 62%, 
      measured by time to all-cause mortality (HR 0.38; 95% CI 0.17, 0.86; 
      nominal p=0.012), and reduced the frequency of cardiovascular 
      hospitalizations by 71% (incidence risk ratio 0.29; 95% CI 0.10, 0.87; 
      nominal p=0.028) compared to placebo in the subgroup with kappa AL 
      amyloidosis. Although anselamimab did not achieve statistical 
      significance for the primary endpoint in its Phase III Cardiac Amyloid 
      Reaching for Extended Survival ("CARES") clinical program for Mayo stages 
      IIIa and IIIb AL amyloidosis patients, the drug showed clinically 
      meaningful improvement in the prespecified subgroup and was well 
      tolerated. AstraZeneca indicated that the company plans to submit the 
      prespecified subgroup analysis from the CARES trials to regulatory 
      authorities and disclosed regulatory submissions in the EU and Japan. 
 
   -- Dotinurad Progresses in Phase 3 Development with Crystalys Series B 
      Financing of $130 million; Initiation of Phase 2 Clinical Trial for 
      Difficult-to-Treat Gout. In July 2026, Crystalys, in which our 
      majority-owned and controlled subsidiary company Urica maintains an 
      equity position, announced a $130 million Series B financing to support 
      the late-stage global clinical development and commercialization 
      preparation for dotinurad. Patients continue to be enrolled in Crystalys' 
      two randomized, double-blind, multicenter global Phase 3 trials 
      evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor 
      with potential for best-in-class safety and efficacy for the treatment of 
      gout. In the second quarter of 2026, Crystalys also announced the 
      initiation of a Phase 2 study in difficult-to-treat gout. 
 
   -- Other Portfolio Programs Continue to Advance with Potential Upcoming Data 
      and Trial Initiations. Triplex is currently in multiple ongoing clinical 
      trials for cytomegalovirus (CMV) treatment and prevention in solid organ 
      and stem cell transplants, combination trials with CAR T cell therapies 
      for hematologic malignancies, and a potential data readout by the end of 
      2026 for prevention and control of CMV in patients co-infected with HIV 
      and CMV. A clinical trial evaluating MB-109, a combination CAR T cell 
      therapy and oncolytic virus, is anticipated to initiate in the fourth 
      quarter of 2026 for patients with IL13R<ALPHA>2-positive recurrent 
      glioblastoma and high-grade astrocytoma. There are also ongoing and 
      planned regulatory interactions with the FDA on trial designs for ATX-04 
      (selective <BETA>2-adrenergic agonist) for patients with Pompe disease 
      and FB-606 (membrane stabilizer) for patients with Duchenne muscular 
      dystrophy. 

Financial Results:

   -- As of June 30, 2026, Fortress' consolidated cash and cash equivalents 
      totaled $196.6 million, compared to $79.4 million as of December 31, 
      2025, an increase of $117.2 million year-to-date. 
 
   -- Fortress' consolidated cash and cash equivalents totaling $196.6 million 
      as of June 30, 2026, includes $153.8 million attributable to Fortress and 
      the private subsidiaries, $1.9 million attributable to Avenue, $15.1 
      million attributable to Mustang Bio and $25.6 million attributable to 
      Journey Medical. 
 
          -- Fortress' consolidated cash and cash equivalents totaled $79.4 
             million as of December 31, 2025, and includes $35.2 million 
             attributable to Fortress and private subsidiaries, $2.9 million 
             attributable to Avenue, $17.3 million attributable to Mustang and 
             $24.1 million attributable to Journey Medical. 
 
   -- Fortress' consolidated net revenue totaled $18.7 million for the second 
      quarter ended June 30, 2026, $17.8 million of which was generated from 
      our marketed dermatology products. This compares to consolidated net 
      revenue totaling $16.4 million for the second quarter of 2025, $15.0 
      million of which was generated from our marketed dermatology products. 
 
   -- Consolidated research and development expenses totaled $0.8 million for 
      the second quarter ended June 30, 2026, compared to $8.1 million for the 
      second quarter ended June 30, 2025. 
 
   -- Consolidated selling, general and administrative costs were $20.8 million 
      for the second quarter ended June 30, 2026, compared to $38.8 million for 
      the second quarter ended June 30, 2025. 
 
   -- Consolidated net loss attributable to common stockholders was $(2.5) 
      million, or $(0.08) per share basic and diluted, for the second quarter 
      ended June 30, 2026, compared to net income attributable to common 
      stockholders of $13.4 million, or $0.50 per share basic, and $0.45 per 
      share diluted, for the second quarter ended June 30, 2025. 

About Fortress Biotech

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children's Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements

Statements in this press release that are not descriptions of historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "might," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to: our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of product candidates under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval or receive royalties or other distributions from third parties; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies' products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contact:

Jaclyn Jaffe

Fortress Biotech, Inc.

(781) 652-4500

ir@fortressbiotech.com

Media Relations Contact:

Tony Plohoros

6 Degrees

(908) 591-2839

tplohoros@6degreespr.com

 
 
               FORTRESS BIOTECH, INC. AND SUBSIDIARIES 
            Unaudited Condensed Consolidated Balance Sheets 
        ($ in thousands except for share and per share amounts) 
 
                                           June 30,     December 31, 
                                             2026           2025 
                                          ----------  ---------------- 
ASSETS 
Current assets 
  Cash and cash equivalents               $ 196,576    $     79,381 
  Accounts receivable, net                   36,246          29,783 
  Inventory                                   8,156           9,624 
  Other receivables - related party             506             158 
  Prepaid expenses and other current 
   assets                                     4,022           4,895 
                                           --------       --------- 
    Total current assets                    245,506         123,841 
 
Property and equipment, net                   2,412           2,519 
Operating lease right-of-use asset, net      11,357          12,302 
Restricted cash                               1,220           1,220 
Equity investments, at fair value            29,451          17,660 
Intangible assets, net                       25,510          27,605 
Other assets                                  1,259             401 
                                           --------       --------- 
Total assets                              $ 316,715    $    185,548 
                                           ========       ========= 
 
LIABILITIES AND STOCKHOLDERS' EQUITY 
Current liabilities 
  Accounts payable and accrued expenses   $  49,325    $     47,125 
  Income taxes payable                        5,179             356 
  Common stock warrant liabilities               --               1 
  Operating lease liabilities, 
   short-term                                 2,246           2,127 
  Partner company notes payable, 
  short-term                                  5,000              -- 
  Other current liabilities                     268             135 
                                           --------       --------- 
    Total current liabilities                62,018          49,744 
 
Notes payable, long-term, net                34,602          52,417 
Operating lease liabilities, long-term       11,468          12,672 
Partner company redeemable perpetual 
 preferred liability                             --           7,085 
Other long-term liabilities                   2,541           1,447 
                                           --------       --------- 
Total liabilities                           110,629         123,365 
                                           --------       --------- 
 
Commitments and contingencies 
 
Stockholders' equity 
Cumulative redeemable perpetual 
 preferred stock, $0.001 par value, 
 15,000,000 authorized, 5,000,000 
 designated Series A shares, 3,427,138 
 shares issued and outstanding as of 
 June 30, 2026 and December 31, 2025, 
 respectively, liquidation value of 
 $25.00 per share                                 3               3 
Common stock, $0.001 par value, 
 200,000,000 shares authorized, 
 33,311,012 and 31,364,094 shares issued 
 and outstanding as of June 30, 2026 and 
 December 31, 2025, respectively                 33              31 
Additional paid-in-capital                  788,251         783,891 
Accumulated deficit                        (624,147)       (734,052) 
                                           --------       --------- 
Total stockholders' equity attributed to 
 the Company                                164,140          49,873 
 
Non-controlling interests                    41,946          12,310 
                                           --------       --------- 
Total stockholders' equity                  206,086          62,183 
                                           --------       --------- 
Total liabilities and stockholders' 
 equity                                   $ 316,715    $    185,548 
                                           ========       ========= 
 
 
 
 
                      FORTRESS BIOTECH, INC. AND SUBSIDIARIES 
              Unaudited CondensedConsolidated Statements of Operations 
              ($ in thousands except for share and per share amounts) 
 
                            Three Months Ended June 
                                      30,               Six Months Ended June 30, 
                           --------------------------  ---------------------------- 
                               2026          2025          2026           2025 
                           ------------  ------------  ------------  -------------- 
Revenue 
  Product revenue, net     $    17,839   $    15,009   $    33,760   $    28,148 
  Other revenue                    879         1,404           996         1,404 
                            ----------    ----------    ----------    ---------- 
Net revenue                     18,718        16,413        34,756        29,552 
                            ----------    ----------    ----------    ---------- 
 
Operating expenses 
Cost of goods - 
 (excluding amortization 
 of acquired intangible 
 assets)                         6,143         4,939        12,361         9,729 
  Amortization of 
   acquired intangible 
   assets                          969         1,064         2,095         2,129 
  Research and 
   development                     805         8,126         1,345        12,060 
  Selling, general and 
   administrative               20,807        38,757        36,699        64,424 
                            ----------    ----------    ----------    ---------- 
Total operating expenses        28,724        52,886        52,500        88,342 
                            ----------    ----------    ----------    ---------- 
Loss from operations           (10,006)      (36,473)      (17,744)      (58,790) 
 
Other income (expense) 
  Interest income                1,581           622         2,151         1,112 
  Interest expense and 
   financing fee                (1,476)       (2,518)       (4,845)       (5,324) 
  Gain on sale of 
  priority review 
  voucher, net of 
  expenses                          --            --       158,873            -- 
  Change in fair value of 
   partner company 
   derivative liability             --            --        (7,085)           -- 
  Gain (loss) on common 
   stock warrant 
   liabilities                      --          (350)            1          (397) 
  Gain from 
   deconsolidation of 
   subsidiary                       82        27,127            82        27,127 
  Other income (expense)        10,741           (62)       11,783           (73) 
                            ----------    ----------    ----------    ---------- 
Total other income              10,928        24,819       160,960        22,445 
                            ----------    ----------    ----------    ---------- 
Income (loss) before 
 income tax expense                922       (11,654)      143,216       (36,345) 
 
Income tax expense                 320            --         5,452            -- 
                            ----------    ----------    ----------    ---------- 
Net income (loss)                  602       (11,654)      137,764       (36,345) 
                            ==========    ==========    ==========    ========== 
 
Attributable to 
 non-controlling 
 interests                      (1,070)       27,140       (27,859)       41,247 
                            ----------    ----------    ----------    ---------- 
Net income (loss) 
 attributable to 
 Fortress                  $      (468)  $    15,486   $   109,905   $     4,902 
                            ==========    ==========    ==========    ========== 
 
Preferred A dividends 
 cumulated, and Fortress' 
 share of subsidiary 
 deemed dividends               (2,008)       (2,131)       (4,016)       (4,261) 
                            ----------    ----------    ----------    ---------- 
Net income (loss) 
 attributable to common 
 stockholders              $    (2,476)  $    13,355   $   105,889   $       640 
                            ==========    ==========    ==========    ========== 
 
Net income (loss) per 
 common share 
 attributable to common 
 stockholders - basic      $     (0.08)  $      0.50   $      3.34   $      0.02 
Net income (loss) per 
 common share 
 attributable to common 
 stockholders - diluted    $     (0.08)  $      0.45   $      2.86   $      0.02 
 
Weighted average common 
 shares outstanding - 
 basic                      31,791,173    26,879,380    31,666,585    26,679,106 
Weighted average common 
 shares outstanding - 
 diluted                    31,791,173    29,824,182    37,011,700    29,182,033 
 
 

___________________________

(1) This press release references products being developed or commercialized by Fortress, by Fortress' private or public subsidiaries (referred to herein as "subsidiaries" or "partner companies") and by entities with whom one of the foregoing parties has a significant business relationship, such as an exclusive license or an ongoing product-related payment obligation (such entities referred to herein as "partners"). The words "we", "us" and "our" may refer to Fortress individually, to one or more of our subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment